blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2016952

EP2016952 - A method of treating a malignancy in a subject and a pharmaceutical composition for use in same [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  31.10.2014
Database last updated on 31.08.2024
Most recent event   Tooltip08.07.2016Lapse of the patent in a contracting state
New state(s): TR		published on 10.08.2016  [2016/32]
Applicant(s)For all designated states
Viralytics Limited
Suite 305
66 Hunter Street
Sydney NSW 2000 / AU
[2013/38]
Former [2009/04]For all designated states
Viralytics Limited
8/33 Ryde Road
Pymble, NSW 2113 / AU
Inventor(s)01 / Shafren, Darren
14 High Street The Hill
Newcastle 2300, NSW / AU
 [2013/52]
Former [2009/30]01 / Shafren, Darren
14 High Street The Hill
Newcastle 2300, NSW / AU
Representative(s)Wakerley, Helen Rachael
Reddie & Grose LLP The White Chapel Building
10 Whitechapel High Street
London E1 8QS / GB
[N/P]
Former [2013/52]Wakerley, Helen Rachael
Reddie & Grose LLP
16 Theobalds Road
London WC1X 8PL / GB
Former [2009/04]Wakerley, Helen Rachael
Reddie & Grose 16 Theobalds Road London
WC1X 8PL / GB
Application number, filing date08018165.427.11.2000
[2009/04]
Priority number, dateAU1999PQ0425625.11.1999         Original published format: AU PQ425699
[2009/04]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP2016952
Date:21.01.2009
Language:EN
[2009/04]
Type: A3 Search report 
No.:EP2016952
Date:19.05.2010
[2010/20]
Type: B1 Patent specification 
No.:EP2016952
Date:25.12.2013
Language:EN
[2013/52]
Search report(s)(Supplementary) European search report - dispatched on:EP16.04.2010
ClassificationIPC:A61K39/12, A61K39/125, A61K39/235, A61K39/245, A61K39/215, A61P35/00, A61P35/04
[2009/04]
CPC:
A61K35/768 (EP,US); A61K9/0019 (US); A61P35/00 (EP);
A61P35/04 (EP); C12N7/00 (US); C12Q1/025 (US);
G01N33/5011 (EP,US); C12N2770/32332 (EP,US); C12N2770/32333 (US);
C12N2770/32371 (US) (-)
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE,   TR [2009/04]
TitleGerman:Verfahren zur Behandlung von Malignomen in einem Patienten und pharmazeutische Zusammensetzung zur Verwendung dafür[2009/04]
English:A method of treating a malignancy in a subject and a pharmaceutical composition for use in same[2009/04]
French:Procédé de traitement d'une tumeur chez un sujet et composition pharmaceutique l'utilisant[2009/04]
Examination procedure13.11.2008Examination requested  [2009/04]
07.03.2011Amendment by applicant (claims and/or description)
27.06.2011Despatch of a communication from the examining division (Time limit: M06)
14.02.2012Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
13.04.2012Reply to a communication from the examining division
09.07.2013Communication of intention to grant the patent
07.11.2013Fee for grant paid
07.11.2013Fee for publishing/printing paid
Parent application(s)   TooltipEP00979268.0  / EP1235590
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20000979268) is  07.10.2005
Opposition(s)26.09.2014No opposition filed within time limit [2014/49]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
13.04.2012Request for further processing filed
13.04.2012Full payment received (date of receipt of payment)
Request granted
27.04.2012Decision despatched
The application is deemed to be withdrawn due to failure to indicate the wish to proceed further with the application
24.02.2011Request for further processing filed
24.02.2011Full payment received (date of receipt of payment)
Request granted
14.03.2011Decision despatched
The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
24.02.2011Request for further processing filed
24.02.2011Full payment received (date of receipt of payment)
Request granted
14.03.2011Decision despatched
Fees paidRenewal fee
13.11.2008Renewal fee patent year 03
13.11.2008Renewal fee patent year 04
13.11.2008Renewal fee patent year 05
13.11.2008Renewal fee patent year 06
13.11.2008Renewal fee patent year 07
13.11.2008Renewal fee patent year 08
13.11.2008Renewal fee patent year 09
12.11.2009Renewal fee patent year 10
12.11.2010Renewal fee patent year 11
14.11.2011Renewal fee patent year 12
13.11.2012Renewal fee patent year 13
18.11.2013Renewal fee patent year 14
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT25.12.2013
BE25.12.2013
CY25.12.2013
DK25.12.2013
FI25.12.2013
NL25.12.2013
SE25.12.2013
TR25.12.2013
GR26.03.2014
PT28.04.2014
[2016/32]
Former [2016/28]AT25.12.2013
BE25.12.2013
CY25.12.2013
DK25.12.2013
FI25.12.2013
NL25.12.2013
SE25.12.2013
GR26.03.2014
PT28.04.2014
Former [2014/48]AT25.12.2013
BE25.12.2013
CY25.12.2013
DK25.12.2013
FI25.12.2013
NL25.12.2013
SE25.12.2013
PT28.04.2014
Former [2014/39]AT25.12.2013
BE25.12.2013
CY25.12.2013
FI25.12.2013
NL25.12.2013
SE25.12.2013
PT28.04.2014
Former [2014/37]AT25.12.2013
BE25.12.2013
CY25.12.2013
FI25.12.2013
SE25.12.2013
PT28.04.2014
Former [2014/34]BE25.12.2013
FI25.12.2013
SE25.12.2013
Former [2014/22]FI25.12.2013
SE25.12.2013
Documents cited:Search[A]WO9918799  (PRO VIRUS INC [US], et al) [A] 1-15 * the whole document *;
 [XI]  - POND A R ET AL, "ONCOLYTIC EFFECT OF POLIOMYELITIS VIRUS ON HUMAN EPIDERMOID CARCINOMA (HELA TUMOR) HETEROLOGOUSLY TRANSPLANTED TO GUINEA PIGS", AMERICAN JOURNAL OF PATHOLOGY, AMERICAN SOCIETY FOR INVESTIGATIVE PATHOLOGY, US, (19640801), vol. 45, ISSN 0002-9440, pages 233 - 249, XP009131699 [X] 1,4-6,10,12,14,15 * the whole document * [I] 3,7-9,13
 [Y]  - NEMUNAITIS J, "ONCOLYTIC VIRUSES", INVESTIGATIONAL NEW DRUGS, MARTINUS NIJHOFF PUBLISHERS, BOSTON, US LNKD- DOI:10.1023/A:1006334404767, (19990101), vol. 17, no. 4, ISSN 0167-6997, pages 375 - 386, XP008022175 [Y] 1-15 * abstract * * page 376, column l, paragraph 2 - paragraph 3 *

DOI:   http://dx.doi.org/10.1023/A:1006334404767
 [Y]  - SHAFREN D R, "Viral cell entry induced by cross-linked decay-accelerating factor", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, (19980101), vol. 72, no. 11, ISSN 0022-538X, pages 9407 - 9412, XP002904990 [Y] 1-15 * page 9408, column r, paragraph 2 * * figure 3B *
 [XPI]  - GROMEIER M ET AL, "Intergeneric poliovirus recombinants for the treatment of malignant glioma.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 6 JUN 2000 LNKD- PUBMED:10841575, (20000606), vol. 97, no. 12, ISSN 0027-8424, pages 6803 - 6808, XP002965080 [XP] 1,4-6,8,10,12,14,15 * the whole document * [I] 3,7,9,13

DOI:   http://dx.doi.org/10.1073/pnas.97.12.6803
 [A]  - SUSKIND R G ET AL, "Viral agents oncolytic for human tumors in heterologous host; oncolytic effect of Coxsackie B viruses.", PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE. SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE (NEW YORK, N.Y.) FEB 1957 LNKD- PUBMED:13408245, (195702), vol. 94, no. 2, ISSN 0037-9727, pages 309 - 318, XP009131831 [A] 1-15 * the whole document *
 [A]  - TAYLOR M W ET AL, "Viruses as an aid to cancer therapy: regression of solid and ascites tumors in rodents after treatment with bovine enterovirus", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA. (PNAS), NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US LNKD- DOI:10.1073/PNAS.68.4.836, (19710401), vol. 68, no. 4, ISSN 0027-8424, pages 836 - 840, XP002526526 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1073/pnas.68.4.836
 [A]  - SEDMAK G V ET AL, "Oncolytic effect of bovine enterovirus on mouse and human tumours.", NATURE: NEW BIOLOGY 5 JUL 1972 LNKD- PUBMED:18663833, (19720705), vol. 238, no. 79, ISSN 0090-0028, pages 7 - 9, XP009131829 [A] 1-15 * the whole document *
 [A]  - MILLER B E ET AL, "Intercellular adhesion molecule-1 (ICAM-1) expression by human melanoma cells: association with leukocyte aggregation and metastatic potential", CLINICAL AND EXPERIMENTAL METASTASIS, SPRINGER NETHERLANDS, NL, (19900101), vol. 8, ISSN 0262-0898, XP002984008 [A] 1-15 * the whole document *
 [L]  - MAIER MICHAEL K ET AL, "The adhesion receptor CD155 determines the magnitude of humoral immune responses against orally ingested antigens.", EUROPEAN JOURNAL OF IMMUNOLOGY AUG 2007 LNKD- PUBMED:17621371, (200708), vol. 37, no. 8, ISSN 0014-2980, pages 2214 - 2225, XP009131815 [L] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1002/eji.200737072
by applicant   - SICKLES G.M., PROC. SOC. EXP. BIOL. MED., vol. 102, page 742
    - SHAFREN D. ET AL., J. VIROL, (1997), vol. 71, page 4736
    - HUGHES ET AL., J. GEN VIROL., (1989), vol. 70, page 2943
    - SCHMIDT, N.J. ET AL., PROC. SOC. EXP. BIOL. MED., (1961), vol. 107, page 63
    - KAGESHITA T ET AL., "Clinical relevance of ICAM-1 expression in primary lesions and serum of patients with malignant melanoma", CANCER RES., (19931015), vol. 53, no. 20, pages 4927 - 32
    - KRAUS A; MASAT L; JOLMSON JP, "Analysis of the expression of intercellular adhesion molecule-1 and MUC18 on benign and malignant melanocytic lesions using monoclonal antibodies directed against distinct epitopes and recognising denatured, non-glycosylated antigen", MELANOMA RES., (19970807), vol. 2, pages 575 - 81
    - MORANDINI R ET AL., "Modulation of ICAM-1 expression by alpha-MSH in human melanoma cells and melanoxytes", J CELL PHYSIOL., (199806), vol. 175, no. 3, pages 276 - 82
    - STAUNTON DE ET AL., "A cell adhesion molecule, ICAM-1 is the major surface receptor for rhinoviruses", CELL, (1989), vol. 56, doi:doi:10.1016/0092-8674(89)90689-2, pages 849 - 853, XP023884492

DOI:   http://dx.doi.org/10.1016/0092-8674(89)90689-2
    - CHEUNG NK ET AL., "Decay-acceleratingfactor protects human tumor cells from complement-mediated cytotoxicity in vitro", J CLIN INVEST., (199804), vol. 81, no. 4, doi:doi:10.1172/JCI113426, pages 1122 - 8, XP002984007

DOI:   http://dx.doi.org/10.1172/JCI113426
    - NEMUNAITIS J, ONCOLYTIC VIRUSES. INVESTIGATIONAL NEW DRUGS, (1999), vol. 17, pages 375 - 386
    - ALEMANY R ET AL., "Gene therapy for gliomas: molecular targets, adenoviral vectors, and oncolytic adenoviruses", EXP CELL RES., (1999), vol. 252, pages 1 - 12
    - ANDREANSKY SS ET AL., "The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors", PROC NATL ACAD SCI USA, (1996), vol. 93, doi:doi:10.1073/pnas.93.21.11313, pages 11313 - 8, XP002207910

DOI:   http://dx.doi.org/10.1073/pnas.93.21.11313
    - COFFEY MC ET AL., "Reovirus therapy of tumours with activated Ras pathway", SCIENCE, (1998), vol. 282, pages 1332 - 1334
    - STRONG JE ET AL., THE MOLECULAR BASIS OF VIRAL ONCOLYSIS: USURPATION OF THE RAS SIGNALLING PATHWAY BY REOVIRUS, (1998), vol. 17, no. 12, pages 3351 - 3362
    - RANDAZZO BP ET AL., "Treatment of experimental intracranial murine melanoma with a neuroattenuated herpes simplex virus l mutant", VIROLOGY, (1995), vol. 211, doi:doi:10.1006/viro.1995.1382, pages 94 - 101, XP000561228

DOI:   http://dx.doi.org/10.1006/viro.1995.1382
    - SATYAMOORTHY K ET AL., "Adenovirus infection enhances killing of melanoma cells by a mitotoxin", CANCER RESEARCH, (1997), vol. 57, pages 1873 - 1876
    - HEMMI S ET AL., "The presence of human Coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures", HUMAN GENE THERAPY, (1998), vol. 9, pages 2363 - 2373, XP001068738
    - SHAFREN DR ET AL., "Coxsackievirus A2.1 binds to decay-accelerating factor but requires intercellular adhesion molecule I for cell entry", J VIROL., (199706), vol. 71, no. 6, pages 4736 - 43, XP002454005
    - BJØRGE L; JENSEN TS; MATRE R, "Characterisation of the complement- regulatory proteins decay-accelerating factnr (DAF, CD55) and membrane cofactor protein (MCP, CD46) on a human colonic adenocarcinoma cell line", CANCER IMMUNOL IMMUNOTHER, (1996), vol. 42, doi:doi:10.1007/s002620050269, pages 185 - 192, XP002984009

DOI:   http://dx.doi.org/10.1007/s002620050269
    - NASU R ET AL., "Immunohistochemical analysis of intercellular adhesion molecule-1 expression in human gastric adenoma and adenocarcinoma", VIRCHOWS ARCH, (1997), vol. 430, pages 279 - 283
    - KOYAMA S; EBIHARA T; FUKAO K, "Expression of intercellular adhesion molecule 1 (ICAM-1) during the development of invasion and/or metastasis of gastric carcinoma", J. CANCER RES. CLIN. ONCOL., (1992), vol. 118, pages 609 - 614
    - ROKHLIN OW; COHEN MB, "Expression ofcellular adhesion molecules on human prostate tumor cell lines", PROSTATE, (199504), vol. 26, no. 4, pages 205 - 12
    - SGAGIAS MK ET AL., "Upregulation of DF3, in association with ICAM-1 and MHC class II by IFN- gamma in short-term human mammary carcinoma cell cultures", CANCER BIOTHER RADIOPHARM., (1996), vol. 11, pages 177 - 85
    - REGIDOR PA ET AL., "Expression of the cell adhesion molecules ICAM·1 and VCAM-1 in the cytosol of breast cancer tissue, benign breast tissue and corresponding sera", EUR J GYNAECOL ONCOL., (1998), vol. 19, pages 377 - 83
    - BACUSS SS ET AL., "Medullary carcinoma is associated with expression of intercellular adhesion molecule-1. Implication to its morphology and its clinical behaviour", AM J PATHOL., (199412), vol. 145, no. 6, pages 1337 - 1148
    - MALONEY DG; DONOVAN K; HAMBLIN TJ, "Antibody therapy for treatment of multiple myeloma", SEMINARS IN HEMATOLOGY, (1999), vol. 36, pages 30 - 33, XP000857401
    - FERNANDEZ-REAL JM ET AL., "Expression of ICAM-1 in distant metastatic thyroid carcinoma", J ENDOCRINOL INVEST., (199603), vol. 19, no. 3, pages 183 - 185
    - NATALIE PG ET AL., "Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule- expression in cutaneous malignant melanoma lesions", CANCER RES., (19970415), vol. 57, no. 8, pages 1554 - 60
    - REED LJ; MUENCH HA, "A simple method of estimatingfifty percent endpoints", AM J HYG., (1938), vol. 27, pages 493 - 497
    - BERENDT AR ET AL., "The binding site on ICAM-1 for plasmodium Jalciparum-infected erythrocytes overlaps, but is distinct from the LFA-1 binding site", CELL, (1992), vol. 68, pages 71 - 81
    - JOHNSON JP ET AL., "The melanoma progression-associated antigen P3.58 is identical to the intercellular adhesion molecule ICAM-1", IMMUNOLOGY, (1988), vol. 178, pages 275 - 284
    - MILLER BE; WELCH DR, "Intercellular adhesion molecule-1. (ICAM-1) expression by human melanoma cells; association with leukocyte aggregation and metastatic potential", CLIN. EXP. METASTASIS., (1990), vol. 8, page 80
    - LEA SM ET AL., "Determination of the affinity and kinetic constants for the interaction between the human virus echovirus 11 and its cellular receptor, CD55", J. BIOL. CHEM., (1998), vol. 273, pages 30443 - 60447
    - DAVIES CDL ET AL., "Comparison of extracellular matrix in human osteosarcomas and melanomas growing as xenogrqfts, multicellular spheroids and monolayer cultures", ANTICANCER RESEARCH., (1997), vol. 17, pages 4317 - 4326
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.